Solvonis Therapeutics (J4I) Financial Statements
Solvonis Therapeutics Financial Overview
Solvonis Therapeutics's market cap is currently $8.97M. The company's EPS TTM is $0.00; its P/E ratio is -1.16; Solvonis Therapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 587.00K | $ 542.00K | $ 219.00K |
| Gross Profit | $ 0.00 | $ 0.00 | $ -134.00K | $ -51.00K | $ 55.00K |
| Operating Income | $ -3.48M | $ -1.38M | $ -2.21M | $ -2.71M | $ -845.00K |
| EBITDA | $ -5.74M | $ -1.38M | $ -2.94M | $ -2.59M | $ -900.00K |
| Net Income | $ -5.74M | $ -1.59M | $ -3.12M | $ -2.71M | $ -954.00K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.72M | $ 757.00K | $ 155.00K | $ 1.64M | $ 598.00K |
| Total Assets | $ 7.58M | $ 3.20M | $ 2.43M | $ 4.94M | $ 3.13M |
| Total Debt | $ 75.00K | $ 0.00 | $ 34.00K | $ 22.00K | $ 950.00K |
| Net Debt | $ -1.65M | $ -757.00K | $ -121.00K | $ -1.62M | $ 352.00K |
| Total Liabilities | $ 1.39M | $ 119.00K | $ 408.00K | $ 385.00K | $ 2.32M |
| Stockholders' Equity | $ 6.19M | $ 3.08M | $ 2.03M | $ 4.55M | $ 812.00K |
| Cash Flow | |||||
| Free Cash Flow | $ -3.27M | $ -1.13M | $ -1.47M | $ -3.08M | $ -255.00K |
| Operating Cash Flow | $ -3.27M | $ -1.13M | $ -1.24M | $ -2.36M | $ -254.00K |
| Investing Cash Flow | $ 0.00 | $ -337.00K | $ -232.00K | $ -718.00K | $ -1.00K |
| Financing Cash Flow | $ 4.23M | $ 2.08M | $ 0.00 | $ 4.13M | $ 800.00K |
Currency in GBP